GLTO

#11858
Damora Therapeutics, Inc. Common Stock
28.69 USD
-0.76%
版块: 医疗保健
基础: USD
利润货币: USD
日范围
28.69
28.69
年范围
2.01
38.33
日变化
-0.76%
每月变动
-6.00%
6个月变化
+917.38%
年变化
+613.68%
前一天收盘价
28.91
开盘价
28.69
买价
卖价
最低价
28.69
High
28.69
交易量
10
展开完整图表

Financials

概览 声明 统计
每季度 年度
  • Market Capitalization 1.6 B
  • Employee 7
  • Founded 2011
  • CEO Hans T. Schambye
  • Website www.damoratx.com
  • Headquarter Delaware, United States
  • FIGI BBG00XMLGWC5
  • Industry 生物技术
总收入
净利润
每股基本收益（基本 EPS）
总债务
自由现金流
现金及现金等价物
市盈率
-5.78
市销率
28.96

Galecto Inc

Galecto Biotech is a biotechnology company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation. The company was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has its operating headquarters in Copenhagen, Denmark. The company builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform. Galecto's lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, in which there is high unmet medical need.

新闻